Literature DB >> 6345130

Protein binding displacement interactions and their clinical importance.

J C McElnay, P F D'Arcy.   

Abstract

The binding of drugs to proteins is an important pharmacokinetic parameter. Many methods are available for the study of drug protein binding phenomena and there are also many ways to interpret the binding data. Although much emphasis has been placed on the binding of drugs in the plasma, binding also takes place in the tissues. Displacement interactions involving plasma or tissue binding sites have been implicated as the causative mechanisms in many drug interactions. However, the importance of plasma binding displacement as a mechanism of drug interactions. However, the importance of plasma binding displacement as a mechanism of drug interaction has been overestimated and overstated, being based largely on in vitro data. Because displaced drug can normally distribute out of the plasma compartment, increases of free drug concentrations are usually transient and therefore will not give rise to changed pharmacological effects in the patient. Those clinically important drug interactions formerly considered to be caused via displacement from plasma binding sites usually have another interaction mechanism involved; commonly decreased metabolism or renal elimination also takes place. Plasma binding displacement interactions, however, do become important clinically in certain specific situations, namely, when the displacing drug is administered quickly to the patient by the intravenous route, during therapeutic drug monitoring, and in certain drug disposition studies which involve the use of a heparin lock for blood sampling. Tissue binding displacement interactions have a greater potential to cause adverse effects in the patient as in this case drug will be forced from extravascular sites back into the plasma. The resulting increased drug plasma levels will lead to enhanced pharmacological effects and, possibly, frank toxicity. Displacement of drugs from binding sites simultaneously in both the plasma and in the tissues will combine the effects seen after displacement from the separate areas. Due to decreased binding in both areas, the free drug concentration in the plasma will increase leading to overactivity of the displaced drug.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6345130     DOI: 10.2165/00003495-198325050-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  91 in total

1.  An in vitro model of drug-albumin interaction [proceedings].

Authors:  J C McElnay; P F Arcy
Journal:  J Pharm Pharmacol       Date:  1977-12       Impact factor: 3.765

2.  Tissue binding of drugs.

Authors:  M Gibaldi; P J McNamara
Journal:  J Pharm Sci       Date:  1977-08       Impact factor: 3.534

3.  Serum protein binding of diphenylhydantoin in man. II. Interaction with sodium valproate in epileptic patients.

Authors:  G Gatti; S Lecchini; G M Frigo; D Visintini; S Calzetti; M Lombardi; G Cattaino
Journal:  Farmaco Prat       Date:  1979-01

4.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

5.  Disopyramide.

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1979-04-26       Impact factor: 91.245

6.  The influence of acetylsalicyclic acid on the binding of acetrizoate to human albumin.

Authors:  R N Pinckard; D Hawkins; R S Farr
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

7.  Effect of heparin administration on plasma binding of benzodiazepines.

Authors:  P V Desmond; R K Roberts; A J Wood; G D Dunn; G R Wilkinson; S Schenker
Journal:  Br J Clin Pharmacol       Date:  1980-02       Impact factor: 4.335

8.  Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids.

Authors:  E M Sellers; J Koch-Weser
Journal:  Clin Pharmacol Ther       Date:  1970 Jul-Aug       Impact factor: 6.875

9.  Phenytoin-valproate interaction: importance of saliva monitoring in epilepsy.

Authors:  C Knott; A Hamshaw-Thomas; F Reynolds
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-02

10.  Phenytoin-salicylate interaction.

Authors:  R F Leonard; P J Knott; G O Rankin; D S Robinson; D E Melnick
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

View more
  22 in total

Review 1.  Antibiotics and breast-feeding: a critical review of the literature.

Authors:  Allison M Chung; Michael D Reed; Jeffrey L Blumer
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 2.  Protein binding drug displacement interactions fact or fiction?

Authors:  J J MacKichan
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

3.  Adjuvant arthritis-induced changes on ampicillin binding in serum and tissues under the influence of non-steroidal anti-inflammatory drugs in rats.

Authors:  E Tigka; I Daskala; G Rallis; S Anagnostopoulou; C Tesseromatis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Oct-Dec       Impact factor: 2.441

4.  Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.

Authors:  Françoise Banères-Roquet; Maxime Gualtieri; Philippe Villain-Guillot; Martine Pugnière; Jean-Paul Leonetti
Journal:  Antimicrob Agents Chemother       Date:  2009-01-21       Impact factor: 5.191

Review 5.  Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.

Authors:  J O Miners
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

Review 6.  The influence of binding to albumin and alpha 1-acid glycoprotein on the clearance of drugs by the liver.

Authors:  D K Meijer; P Van der Sluijs
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

7.  Interaction of mixed micelles formed from glycocholic acid and lecithin with the protein binding of various drugs.

Authors:  T W Guentert; S Oie; L Paalzow; B M Frey; R Brandt; L J Aarons; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

8.  Serum protein binding of tolbutamide in patients treated with antiepileptic drugs.

Authors:  M C Fernández; S Erill; M I Lucena; E Pita; N Pérez-Alférez
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

9.  Albumin-Based Transport of Nonsteroidal Anti-Inflammatory Drugs in Mammalian Blood Plasma.

Authors:  Mateusz P Czub; Katarzyna B Handing; Barat S Venkataramany; David R Cooper; Ivan G Shabalin; Wladek Minor
Journal:  J Med Chem       Date:  2020-06-17       Impact factor: 7.446

10.  In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite.

Authors:  J M Machinist; M J Kukulka; B A Bopp
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.